up-to-date with a click!
Update January, 2019
 
Curated by Peter Lansberg,
a Dutch lipidologist and educator, and
reviewed by prof. Philip Barter, Past President of the
International Atherosclerosis Society.
The IAS Statin Newsletter will keep you up-to-date with all recent statin publications, using a curated approach to select relevant articles.

Statin publications January 2019

Add on treatment

  1. Kazi DS, Penko J, Coxson PG et al. Cost-Effectiveness of Alirocumab: A Just-in-Time Analysis Based on the ODYSSEY Outcomes Trial. Annals of internal medicine 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30597485
  2. Navar AM, Roe MT, White JA et al. Medication Discontinuation in the IMPROVE-IT Trial. Circ Cardiovasc Qual Outcomes 2019; 12:e005041. http://www.ncbi.nlm.nih.gov/pubmed/?term=30630361
  3. Ronnqvist J, Hallberg P, Yue QY, Wadelius M. Fusidic Acid: A Neglected Risk Factor for Statin-Associated Myopathy. Clinical Medicine Insights. Cardiology 2018; 12:1179546818815162. http://www.ncbi.nlm.nih.gov/pubmed/?term=30618488
  4. Hong SJ, Jeong HS, Cho JM et al. Efficacy and Safety of Triple Therapy With Telmisartan, Amlodipine, and Rosuvastatin in Patients With Dyslipidemia and Hypertension: The Jeil Telmisartan, Amlodipine, and Rosuvastatin Randomized Clinical Trial. Clinical therapeutics 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30665829
  5. Preston Mason R. New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease. Curr Atheroscler Rep 2019; 21:2. http://www.ncbi.nlm.nih.gov/pubmed/?term=30637567
  6. Li F, Zheng X, Bao Y et al. Fenofibrate modified-release pellets with lag phase and high oral bioavailability. Drug design, development and therapy 2019; 13:141-151. http://www.ncbi.nlm.nih.gov/pubmed/?term=30613135
  7. Rasmussen DB, Bodtger U, Lamberts M et al. Beta-blocker, aspirin and statin usage after first-time myocardial infarction in patients with chronicAuthor information obstructive pulmonary disease: a nationwide analysis from 1995 to 2015 in Denmark. European heart journal. Quality of care & clinical outcomes 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30608575
  8. El-Refai SM, Brown JD, Arnold SM et al. Epidemiologic Analysis Along the Mevalonate Pathway Reveals Improved Cancer Survival in Patients Who Receive Statins Alone and in Combination With Bisphosphonates. JCO clinical cancer informatics 2017; 1:1-12. http://www.ncbi.nlm.nih.gov/pubmed/?term=30657380
  9. Smith SM. ARB superiority over ACE inhibitors in Coronary Heart Disease: An Alternative Viewpoint. Pharmacotherapy 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30633371
  10. Ezetimibe + statin: insufficient benefit. Prescrire international 2016; 25:245-246. http://www.ncbi.nlm.nih.gov/pubmed/?term=30645833

Adherence

  1. Navar AM, Roe MT, White JA et al. Medication Discontinuation in the IMPROVE-IT Trial. Circ Cardiovasc Qual Outcomes 2019; 12:e005041. http://www.ncbi.nlm.nih.gov/pubmed/?term=30630361
  2. Reklou A, Katsiki N, Karagiannis A, Athyros V. Effects of lipid lowering drugs on arterial stiffness. One more way to reduce cardiovascular risk? Current vascular pharmacology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30663570
  3. Colantonio LD, Rosenson RS, Deng L et al. Adherence to Statin Therapy Among US Adults Between 2007 and 2014. J Am Heart Assoc 2019; 8:e010376. http://www.ncbi.nlm.nih.gov/pubmed/?term=30616455
  4. Peverelle MR, Baradi A, Paleri S et al. Higher long-term adherence to statins in rural patients at high atherosclerotic risk. J Clin Lipidol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30594444
  5. Sarpatwari A, Gagne JJ, Lu Z et al. A Survey of Patients' Perceptions of Pill Appearance and Responses to Changes in Appearance for Four Chronic Disease Medications. Journal of general internal medicine 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30632102
  6. Khunti K, Danese MD, Kutikova L et al. Association of a Combined Measure of Adherence and Treatment Intensity With Cardiovascular Outcomes in Patients With Atherosclerosis or Other Cardiovascular Risk Factors Treated With Statins and/or Ezetimibe. JAMA network open 2018; 1:e185554. http://www.ncbi.nlm.nih.gov/pubmed/?term=30646277
  7. Streja E, Gosmanova EO, Molnar MZ et al. Association of Continuation of Statin Therapy Initiated Before Transition to Chronic Dialysis Therapy With Mortality After Dialysis Initiation. JAMA network open 2018; 1:e182311. http://www.ncbi.nlm.nih.gov/pubmed/?term=30646217
  8. Hope HF, Binkley GM, Fenton S et al. Systematic review of the predictors of statin adherence for the primary prevention of cardiovascular disease. PLoS One 2019; 14:e0201196. http://www.ncbi.nlm.nih.gov/pubmed/?term=30653535
  9. Vethe NT, Munkhaugen J, Andersen AM et al. A Method for Direct Monitoring of Atorvastatin Adherence in Cardiovascular Disease Prevention: Quantification of the Total Exposure to Parent Drug and Major Metabolites Using 2-Channel Chromatography and Tandem Mass Spectrometry. Therapeutic drug monitoring 2019; 41:19-28. http://www.ncbi.nlm.nih.gov/pubmed/?term=30633723

Atherosclerosis & Imaging

  1. Vuorio A, Watts GF, Kovanen PT. Lipoprotein(a) as a risk factor for calcific aortic valvulopathy in heterozygous familial hypercholesterolemia. Atherosclerosis 2018; 281:25-30. http://www.ncbi.nlm.nih.gov/pubmed/?term=30616181
  2. Miname MH, Bittencourt MS, Nasir K, Santos RD. Subclinical coronary atherosclerosis and cardiovascular risk stratification in heterozygous familial hypercholesterolemia patients undergoing statin treatment. Curr Opin Lipidol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30649025
  3. Kanaya AM, Vittinghoff E, Lin F et al. Incidence and Progression of Coronary Artery Calcium in South Asians Compared With 4 Race/Ethnic Groups. J Am Heart Assoc 2019; 8:e011053. http://www.ncbi.nlm.nih.gov/pubmed/?term=30630376
  4. Seo JH, Chun KJ, Lee BK et al. Statins Have No Role in Preventing the Progression of Aortic Valve Sclerosis. Journal of cardiovascular imaging 2018; 26:229-237. http://www.ncbi.nlm.nih.gov/pubmed/?term=30607391
  5. Thassakorn P, Patchanee P, Pongkan W et al. Effect of atorvastatin on oxidative stress and inflammation markers in myxomatous mitral valve disease in dogs: A comparison of subclinical and clinical stages. Journal of veterinary pharmacology and therapeutics 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30666669
  6. Almeida SO, Budoff M. Effect of statins on atherosclerotic plaque. Trends Cardiovasc Med 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30642643

Atorvastatin/Rosuvastatin

  1. Li X, Dardik A, Guo R et al. Atorvastatin regulates pericardial patch healing via the microRNA140-ADAM10-ephrinB2 pathway. American journal of translational research 2018; 10:4054-4064. http://www.ncbi.nlm.nih.gov/pubmed/?term=30662650
  2. Wang X, Chong S, Lin H et al. Discovery of atorvastatin as a tetramer stabilizer of nuclear receptor RXRalpha through structure-based virtual screening. Bioorganic chemistry 2019; 85:413-419. http://www.ncbi.nlm.nih.gov/pubmed/?term=30665035
  3. Rodriguez-Perea AL, Rojas M, Velilla-Hernandez PA. High concentrations of atorvastatin reduce in vitro function of conventional T and regulatory T cells. Clinical and experimental immunology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30638266
  4. Hong SJ, Jeong HS, Cho JM et al. Efficacy and Safety of Triple Therapy With Telmisartan, Amlodipine, and Rosuvastatin in Patients With Dyslipidemia and Hypertension: The Jeil Telmisartan, Amlodipine, and Rosuvastatin Randomized Clinical Trial. Clinical therapeutics 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30665829
  5. Doumas M, Imprialos K, Dimakopoulou A et al. The role of statins in the management of nonalcoholic fatty liver disease. Current pharmaceutical design 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30652643
  6. Kameda A, Nakamura A, Kondo Y et al. Effects of switching to low-dose rosuvastatin (5 mg/day) on glucose metabolism and lipid profiles in Japanese patients with type 2 diabetes and dyslipidemia: a single-arm, prospective, interventional trial. Diabetology international 2017; 8:383-391. http://www.ncbi.nlm.nih.gov/pubmed/?term=30603344
  7. El-Korashi LA, Soliman MH, Attwa EM, Mohamed NA. Role of Atorvastatin in Treatment of Chronic Spontaneous Urticaria Patients: A Controlled Clinical Trial. The Egyptian journal of immunology 2018; 25:133-139. http://www.ncbi.nlm.nih.gov/pubmed/?term=30600956
  8. Ye Z, Lu H, Su Q et al. Short-term and long-term effects of a loading dose of atorvastatin before percutaneous coronary intervention on major adverse cardiovascular events in patients with acute coronary syndrome: a meta-analysis of 13 randomized controlled trials. Eur Heart J 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30608526
  9. Lamy A, Lonn E, Tong W et al. The cost implication of primary prevention in the HOPE 3 trial. European heart journal. Quality of care & clinical outcomes 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30657891
  10. An L, An S, Jia Z et al. Atorvastatin improves left ventricular remodeling and cardiac function in rats with congestive heart failure by inhibiting RhoA/Rho kinase-mediated endothelial nitric oxide synthase. Experimental and therapeutic medicine 2019; 17:960-966. http://www.ncbi.nlm.nih.gov/pubmed/?term=30651887
  11. Ma G, Bi S. Effect of rosuvastatin on vascular endothelial functions and inflammatory factors of patients with type 2 diabetes mellitus and coronary heart disease. Experimental and therapeutic medicine 2019; 17:332-336. http://www.ncbi.nlm.nih.gov/pubmed/?term=30651799
  12. Agrawal D, Manchanda SC, Sawhney JPS et al. To study the effect of high dose Atorvastatin 40mg versus 80mg in patients with dyslipidemia. Indian Heart J 2018; 70 Suppl 3:S8-s12. http://www.ncbi.nlm.nih.gov/pubmed/?term=30595326
  13. Kumar M, Rehan HS, Puri R et al. Randomized controlled trial comparing the efficacy of daily and every other day atorvastatin therapy and its correlation with serum hydroxymethylglutaryl-CoA reductase enzyme levels in naive dyslipidemic patients. Indian Heart J 2018; 70 Suppl 3:S64-s67. http://www.ncbi.nlm.nih.gov/pubmed/?term=30595323
  14. Ramakumari N, Indumathi B, Katkam SK, Kutala VK. Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects. Indian Heart J 2018; 70 Suppl 3:S120-s125. http://www.ncbi.nlm.nih.gov/pubmed/?term=30595243
  15. Pourhosseini H, Lashkari R, Aminorroaya A et al. Effects of high dose atorvastatin before elective percutaneous coronary intervention on highly sensitive troponin T and one year major cardiovascular events; a randomized clinical trial. International journal of cardiology. Heart & vasculature 2019; 22:96-101. http://www.ncbi.nlm.nih.gov/pubmed/?term=30671535
  16. Najafipour M, Zareizadeh M, Khokhi MA, Najafipour F. Comparative study of the effect of atorvastatin and fenofibrate on high-density lipoprotein cholesterol levels in patients with type 2 diabetes. Journal of advanced pharmaceutical technology & research 2018; 9:135-138. http://www.ncbi.nlm.nih.gov/pubmed/?term=30637231
  17. Aktay G, Gursoy SO, Uyumlu U et al. Protective effect of atorvastatin on oxidative stress in streptozotocin-induced diabetic rats independently their lipid-lowering effects. Journal of biochemical and molecular toxicology 2019:e22295. http://www.ncbi.nlm.nih.gov/pubmed/?term=30657622
  18. Nabati M, Janbabai G, Esmailian J, Yazdani J. Effect of Rosuvastatin in Preventing Chemotherapy-Induced Cardiotoxicity in Women With Breast Cancer: A Randomized, Single-Blind, Placebo-Controlled Trial. Journal of cardiovascular pharmacology and therapeutics 2019:1074248418821721. http://www.ncbi.nlm.nih.gov/pubmed/?term=30599756
  19. Pirro M, Simental-Mendia LE, Bianconi V et al. Effect of Statin Therapy on Arterial Wall Inflammation Based on 18F-FDG PET/CT: A Systematic Review and Meta-Analysis of Interventional Studies. Journal of clinical medicine 2019; 8. http://www.ncbi.nlm.nih.gov/pubmed/?term=30669380
  20. Thassakorn P, Patchanee P, Pongkan W et al. Effect of atorvastatin on oxidative stress and inflammation markers in myxomatous mitral valve disease in dogs: A comparison of subclinical and clinical stages. Journal of veterinary pharmacology and therapeutics 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30666669
  21. Khunti K, Danese MD, Kutikova L et al. Association of a Combined Measure of Adherence and Treatment Intensity With Cardiovascular Outcomes in Patients With Atherosclerosis or Other Cardiovascular Risk Factors Treated With Statins and/or Ezetimibe. JAMA network open 2018; 1:e185554. http://www.ncbi.nlm.nih.gov/pubmed/?term=30646277
  22. Patel MS, Kurtzman GW, Kannan S et al. Effect of an Automated Patient Dashboard Using Active Choice and Peer Comparison Performance Feedback to Physicians on Statin Prescribing: The PRESCRIBE Cluster Randomized Clinical Trial. JAMA network open 2018; 1:e180818. http://www.ncbi.nlm.nih.gov/pubmed/?term=30646039
  23. Sommella E, Badolati N, Riccio G et al. A Boost in Mitochondrial Activity Underpins the Cholesterol-Lowering Effect of Annurca Apple Polyphenols on Hepatic Cells. Nutrients 2019; 11. http://www.ncbi.nlm.nih.gov/pubmed/?term=30646510
  24. Lu Y, Chang R, Yao J et al. Effectiveness of long-term using statins in COPD - a network meta-analysis. Respiratory research 2019; 20:17. http://www.ncbi.nlm.nih.gov/pubmed/?term=30674312

Basic science

  1. Liyanage ADT, Chen AJ, Puleo DA. Biodegradable Simvastatin-Containing Polymeric Prodrugs with Improved Drug Release. ACS biomaterials science & engineering 2018; 4:4193-4199. http://www.ncbi.nlm.nih.gov/pubmed/?term=30631799
  2. Li X, Dardik A, Guo R et al. Atorvastatin regulates pericardial patch healing via the microRNA140-ADAM10-ephrinB2 pathway. American journal of translational research 2018; 10:4054-4064. http://www.ncbi.nlm.nih.gov/pubmed/?term=30662650
  3. Novosvetska L, Chocholous P, Svec F, Sklenarova H. Fully automated method based on on-line molecularly imprinted polymer solid-phase extraction for determination of lovastatin in dietary supplements containing red yeast rice. Analytical and bioanalytical chemistry 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30617392
  4. Falfushynska H, Sokolov EP, Haider F et al. Effects of a common pharmaceutical, atorvastatin, on energy metabolism and detoxification mechanisms of a marine bivalve Mytilus edulis. Aquatic toxicology (Amsterdam, Netherlands) 2018; 208:47-61. http://www.ncbi.nlm.nih.gov/pubmed/?term=30610964
  5. Zhao Z, Zhong L, He K et al. Cholesterol attenuated the progression of DEN-induced hepatocellular carcinoma via inhibiting SCAP mediated fatty acid de novo synthesis. Biochem Biophys Res Commun 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30638930
  6. Wang X, Chong S, Lin H et al. Discovery of atorvastatin as a tetramer stabilizer of nuclear receptor RXRalpha through structure-based virtual screening. Bioorganic chemistry 2019; 85:413-419. http://www.ncbi.nlm.nih.gov/pubmed/?term=30665035
  7. Takahashi T, Uno Y, Yamazaki H, Kume T. Functional characterization for polymorphic organic anion transporting polypeptides (OATP/SLCO1B1, 1B3, 2B1) of monkeys recombinantly expressed with various OATP probes. Biopharmaceutics & drug disposition 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30652318
  8. Raafat SN. Response to letter to the editor: The sole and combined effect of simvastatin and platelet rich fibrin as a filling material in induced bone defect in tibia of albino rats. Bone 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30612981
  9. Carrer A, Trefely S, Zhao S et al. Acetyl-CoA metabolism supports multi-step pancreatic tumorigenesis. Cancer discovery 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30626590
  10. Rodriguez-Perea AL, Rojas M, Velilla-Hernandez PA. High concentrations of atorvastatin reduce in vitro function of conventional T and regulatory T cells. Clinical and experimental immunology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30638266
  11. Li F, Zheng X, Bao Y et al. Fenofibrate modified-release pellets with lag phase and high oral bioavailability. Drug design, development and therapy 2019; 13:141-151. http://www.ncbi.nlm.nih.gov/pubmed/?term=30613135
  12. Auti P, Gabhe S, Mahadik K. Bioanalytical method development and its application to pharmacokinetics studies on Simvastatin in the presence of Piperine and two of its synthetic derivatives. Drug development and industrial pharmacy 2019:1-17. http://www.ncbi.nlm.nih.gov/pubmed/?term=30649976
  13. An L, An S, Jia Z et al. Atorvastatin improves left ventricular remodeling and cardiac function in rats with congestive heart failure by inhibiting RhoA/Rho kinase-mediated endothelial nitric oxide synthase. Experimental and therapeutic medicine 2019; 17:960-966. http://www.ncbi.nlm.nih.gov/pubmed/?term=30651887
  14. Zhang ZZ, Zhang HZ, Zhang ZY. 3D printed poly(epsilon-caprolactone) scaffolds function with simvastatin-loaded poly(lactic-co-glycolic acid) microspheres to repair load-bearing segmental bone defects. Experimental and therapeutic medicine 2019; 17:79-90. http://www.ncbi.nlm.nih.gov/pubmed/?term=30651767
  15. Zhang J, Shi X, Hao N et al. Simvastatin Reduces Neutrophils Infiltration Into Brain Parenchyma After Intracerebral Hemorrhage via Regulating Peripheral Neutrophils Apoptosis. Frontiers in neuroscience 2018; 12:977. http://www.ncbi.nlm.nih.gov/pubmed/?term=30631264
  16. Mo H, Jeter R, Bachmann A et al. The Potential of Isoprenoids in Adjuvant Cancer Therapy to Reduce Adverse Effects of Statins. Frontiers in pharmacology 2018; 9:1515. http://www.ncbi.nlm.nih.gov/pubmed/?term=30662405
  17. Ooi KG, Rao A, Goh JS et al. HMG-CoA reductase expression in human eyelid tissue and in a human meibomian gland epithelial cell line. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30666404
  18. Aktay G, Gursoy SO, Uyumlu U et al. Protective effect of atorvastatin on oxidative stress in streptozotocin-induced diabetic rats independently their lipid-lowering effects. Journal of biochemical and molecular toxicology 2019:e22295. http://www.ncbi.nlm.nih.gov/pubmed/?term=30657622
  19. Encarnacao IC, Sordi MB, Aragones A et al. Release of simvastatin from scaffolds of poly(lactic-co-glycolic) acid and biphasic ceramic designed for bone tissue regeneration. Journal of biomedical materials research. Part B, Applied biomaterials 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30653823
  20. Paseban M, Butler AE, Sahebkar A. Mechanisms of statin-induced new-onset diabetes. Journal of cellular physiology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30618154
  21. Mouafi FE, Ibrahim GS, Abo Elsoud MM. Optimization of lovastatin production from Aspergillus fumigatus. Journal, genetic engineering & biotechnology 2016; 14:253-259. http://www.ncbi.nlm.nih.gov/pubmed/?term=30647623
  22. Tanaka T, Matsushita T, Nishida K et al. Attenuation of osteoarthritis progression in mice following intra-articular administration of simvastatin-conjugated gelatin hydrogel. Journal of tissue engineering and regenerative medicine 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30644168
  23. Thassakorn P, Patchanee P, Pongkan W et al. Effect of atorvastatin on oxidative stress and inflammation markers in myxomatous mitral valve disease in dogs: A comparison of subclinical and clinical stages. Journal of veterinary pharmacology and therapeutics 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30666669
  24. de Faria CA, Zanette DL, Silva WA, Jr., Ribeiro-Paes JT. PAI-1 inhibition by simvastatin as a positive adjuvant in cell therapy. Molecular biology reports 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30612281
  25. Zhao WB, Fu H, Chang F et al. Effects of various doses of atorvastatin on vascular endothelial cell apoptosis and autophagy in vitro. Mol Med Rep 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30628690
  26. Zheng XF, Liu KX, Wang XM et al. MicroRNA192 acts as a tumor suppressor in colon cancer and simvastatin activates miR192 to inhibit cancer cell growth. Mol Med Rep 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30628692
  27. Sommella E, Badolati N, Riccio G et al. A Boost in Mitochondrial Activity Underpins the Cholesterol-Lowering Effect of Annurca Apple Polyphenols on Hepatic Cells. Nutrients 2019; 11. http://www.ncbi.nlm.nih.gov/pubmed/?term=30646510
  28. Vethe NT, Munkhaugen J, Andersen AM et al. A Method for Direct Monitoring of Atorvastatin Adherence in Cardiovascular Disease Prevention: Quantification of the Total Exposure to Parent Drug and Major Metabolites Using 2-Channel Chromatography and Tandem Mass Spectrometry. Therapeutic drug monitoring 2019; 41:19-28. http://www.ncbi.nlm.nih.gov/pubmed/?term=30633723
  29. Jin H, He Y, Zhao P et al. Targeting lipid metabolism to overcome EMT-associated drug resistance via integrin beta3/FAK pathway and tumor-associated macrophage repolarization using legumain-activatable delivery. Theranostics 2019; 9:265-278. http://www.ncbi.nlm.nih.gov/pubmed/?term=30662566
  30. Kim TH, Yun YP, Shim KS et al. In Vitro Anti-Inflammation and Chondrogenic Differentiation Effects of Inclusion Nanocomplexes of Hyaluronic Acid-Beta Cyclodextrin and Simvastatin. Tissue engineering and regenerative medicine 2018; 15:263-274. http://www.ncbi.nlm.nih.gov/pubmed/?term=30603552
  31. Beverly BEJ, Furr JR, Lambright CS et al. In utero exposure to simvastatin reduces postnatal survival and permanently alters reproductive tract development in the Crl:CD(SD) male rat. Toxicology and applied pharmacology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=3063941

Cancer

  1. Zhao Z, Zhong L, He K et al. Cholesterol attenuated the progression of DEN-induced hepatocellular carcinoma via inhibiting SCAP mediated fatty acid de novo synthesis. Biochem Biophys Res Commun 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30638930
  2. Borgquist S, Broberg P, Tojjar J, Olsson H. Statin use and breast cancer survival - a Swedish nationwide study. BMC Cancer 2019; 19:54. http://www.ncbi.nlm.nih.gov/pubmed/?term=30634941
  3. Carrer A, Trefely S, Zhao S et al. Acetyl-CoA metabolism supports multi-step pancreatic tumorigenesis. Cancer discovery 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30626590
  4. Thrift AP, Natarajan Y, Liu Y, El-Serag HB. Statin use after diagnosis of hepatocellular carcinoma and patient survival: findings from a retrospective cohort study. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30625400
  5. Jamil A, Mirza MA, Anwer K et al. Co-delivery of Gemcitabine and Simvastatin through PLGA polymeric nanoparticles for thetreatment of pancreatic cancer: In-vitro characterization, cellular uptake and pharmacokinetic studies. Drug development and industrial pharmacy 2019:1-34. http://www.ncbi.nlm.nih.gov/pubmed/?term=30632800
  6. Mo H, Jeter R, Bachmann A et al. The Potential of Isoprenoids in Adjuvant Cancer Therapy to Reduce Adverse Effects of Statins. Frontiers in pharmacology 2018; 9:1515. http://www.ncbi.nlm.nih.gov/pubmed/?term=30662405
  7. Matsuo K, Hom MS, Yabuno A et al. Association of statins, aspirin, and venous thromboembolism in women with endometrial cancer. Gynecologic oncology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30616901
  8. Menon S, Mathew R. Association between metabolic syndrome and hepatobiliary cancers: A case-control study. Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30628006
  9. Nabati M, Janbabai G, Esmailian J, Yazdani J. Effect of Rosuvastatin in Preventing Chemotherapy-Induced Cardiotoxicity in Women With Breast Cancer: A Randomized, Single-Blind, Placebo-Controlled Trial. Journal of cardiovascular pharmacology and therapeutics 2019:1074248418821721. http://www.ncbi.nlm.nih.gov/pubmed/?term=30599756
  10. El-Refai SM, Brown JD, Arnold SM et al. Epidemiologic Analysis Along the Mevalonate Pathway Reveals Improved Cancer Survival in Patients Who Receive Statins Alone and in Combination With Bisphosphonates. JCO clinical cancer informatics 2017; 1:1-12. http://www.ncbi.nlm.nih.gov/pubmed/?term=30657380
  11. Omori M, Okuma Y, Hakozaki T, Hosomi Y. Statins improve survival in patients previously treated with nivolumab for advanced non-small cell lung cancer: An observational study. Molecular and clinical oncology 2019; 10:137-143. http://www.ncbi.nlm.nih.gov/pubmed/?term=30655989
  12. Zhao WB, Fu H, Chang F et al. Effects of various doses of atorvastatin on vascular endothelial cell apoptosis and autophagy in vitro. Mol Med Rep 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30628690
  13. Zheng XF, Liu KX, Wang XM et al. MicroRNA192 acts as a tumor suppressor in colon cancer and simvastatin activates miR192 to inhibit cancer cell growth. Mol Med Rep 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30628692
  14. Zhang Y, Liang M, Sun C et al. Statin Use and Risk of Pancreatic Cancer: An Updated Meta-analysis of 26 Studies. Pancreas 2019; 48:142-150. http://www.ncbi.nlm.nih.gov/pubmed/?term=30640225
  15. Chen Y, Li X, Zhang R et al. Effects of statin exposure and lung cancer survival: A meta-analysis of observational studies. Pharmacol Res 2019; 141:357-365. http://www.ncbi.nlm.nih.gov/pubmed/?term=30641276
  16. Joentausta RM, Rannikko A, Murtola TJ. Prostate cancer survival among statin users after prostatectomy in a Finnish nationwide cohort. Prostate 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30652328
  17. Jin H, He Y, Zhao P et al. Targeting lipid metabolism to overcome EMT-associated drug resistance via integrin beta3/FAK pathway and tumor-associated macrophage repolarization using legumain-activatable delivery. Theranostics 2019; 9:265-278. http://www.ncbi.nlm.nih.gov/pubmed/?term=30662566

Cost-effectiveness

  1. Kazi DS, Penko J, Coxson PG et al. Cost-Effectiveness of Alirocumab: A Just-in-Time Analysis Based on the ODYSSEY Outcomes Trial. Annals of internal medicine 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30597485
  2. Lamy A, Lonn E, Tong W et al. The cost implication of primary prevention in the HOPE 3 trial. European heart journal. Quality of care & clinical outcomes 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30657891
  3. Hynninen Y, Linna M, Vilkkumaa E. Value of genetic testing in the prevention of coronary heart disease events. PLoS One 2019; 14:e0210010. http://www.ncbi.nlm.nih.gov/pubmed/?term=30645616

CVD

  1. Zhou Y, Yao X, Liu G et al. Level and variation on quality of care in China: a cross-sectional study for the acute myocardial infarction patients in tertiary hospitals in Beijing. BMC Health Serv Res 2019; 19:43. http://www.ncbi.nlm.nih.gov/pubmed/?term=30658628
  2. Moayedi Y, Kozuszko S, Knowles JW et al. Safety and Efficacy of PCSK9 Inhibitors After Heart Transplantation. Can J Cardiol 2019; 35:104.e101-104.e103. http://www.ncbi.nlm.nih.gov/pubmed/?term=30595172
  3. Chaudhary R, Kinderyte M, Chaudhary R et al. HDL3-C is a marker of coronary artery disease severity and inflammation in patients on statin therapy. Cardiovascular revascularization medicine : including molecular interventions 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30626544
  4. Ye Z, Lu H, Su Q et al. Short-term and long-term effects of a loading dose of atorvastatin before percutaneous coronary intervention on major adverse cardiovascular events in patients with acute coronary syndrome: a meta-analysis of 13 randomized controlled trials. Eur Heart J 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30608526
  5. Ma G, Bi S. Effect of rosuvastatin on vascular endothelial functions and inflammatory factors of patients with type 2 diabetes mellitus and coronary heart disease. Experimental and therapeutic medicine 2019; 17:332-336. http://www.ncbi.nlm.nih.gov/pubmed/?term=30651799
  6. Kaplan DE, Serper M, Mehta R et al. Effects of Hypercholesterolemia and Statin Exposure on Survival in a Large National Cohort of Patients With Cirrhosis. Gastroenterology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30660733
  7. Nixdorff U, Horstick G, Schlitt A. [Acute coronary syndrome : Prevention]. Herz 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30671595
  8. Pourhosseini H, Lashkari R, Aminorroaya A et al. Effects of high dose atorvastatin before elective percutaneous coronary intervention on highly sensitive troponin T and one year major cardiovascular events; a randomized clinical trial. International journal of cardiology. Heart & vasculature 2019; 22:96-101. http://www.ncbi.nlm.nih.gov/pubmed/?term=30671535
  9. Nabati M, Janbabai G, Esmailian J, Yazdani J. Effect of Rosuvastatin in Preventing Chemotherapy-Induced Cardiotoxicity in Women With Breast Cancer: A Randomized, Single-Blind, Placebo-Controlled Trial. Journal of cardiovascular pharmacology and therapeutics 2019:1074248418821721. http://www.ncbi.nlm.nih.gov/pubmed/?term=30599756
  10. Fan W, Philip S, Granowitz C et al. Hypertriglyceridemia in statin-treated US adults: the National Health and Nutrition Examination Survey. J Clin Lipidol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30594443
  11. Peverelle MR, Baradi A, Paleri S et al. Higher long-term adherence to statins in rural patients at high atherosclerotic risk. J Clin Lipidol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30594444
  12. Fang T, Guo B, Xue L, Wang L. Atorvastatin Prevents Myocardial Fibrosis in Spontaneous Hypertension via Interleukin-6 (IL-6)/Signal Transducer and Activator of Transcription 3 (STAT3)/Endothelin-1 (ET-1) Pathway. Medical science monitor : international medical journal of experimental and clinical research 2019; 25:318-323. http://www.ncbi.nlm.nih.gov/pubmed/?term=30631031

Endothelium/inflammation

  1. Rodriguez-Perea AL, Rojas M, Velilla-Hernandez PA. High concentrations of atorvastatin reduce in vitro function of conventional T and regulatory T cells. Clinical and experimental immunology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30638266
  2. Devaraj S, Siegel D, Jialal I. Correction to: Statin Therapy in Metabolic Syndrome and Hypertension Post-JUPITER: What is the Value of CRP? Curr Atheroscler Rep 2019; 21:3. http://www.ncbi.nlm.nih.gov/pubmed/?term=30662999
  3. Khadir A, Kavalakatt S, Dehbi M et al. DUSP1 Is a Potential Marker of Chronic Inflammation in Arabs with Cardiovascular Diseases. Disease markers 2018; 2018:9529621. http://www.ncbi.nlm.nih.gov/pubmed/?term=30647800
  4. Pirro M, Simental-Mendia LE, Bianconi V et al. Effect of Statin Therapy on Arterial Wall Inflammation Based on 18F-FDG PET/CT: A Systematic Review and Meta-Analysis of Interventional Studies. Journal of clinical medicine 2019; 8. http://www.ncbi.nlm.nih.gov/pubmed/?term=30669380
  5. Thassakorn P, Patchanee P, Pongkan W et al. Effect of atorvastatin on oxidative stress and inflammation markers in myxomatous mitral valve disease in dogs: A comparison of subclinical and clinical stages. Journal of veterinary pharmacology and therapeutics 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30666669
  6. Sorensen AL, Hasselbalch HC, Nielsen CH et al. Statin treatment, oxidative stress and inflammation in a Danish population. Redox biology 2018; 21:101088. http://www.ncbi.nlm.nih.gov/pubmed/?term=30594900
  7. Kim TH, Yun YP, Shim KS et al. In Vitro Anti-Inflammation and Chondrogenic Differentiation Effects of Inclusion Nanocomplexes of Hyaluronic Acid-Beta Cyclodextrin and Simvastatin. Tissue engineering and regenerative medicine 2018; 15:263-274. http://www.ncbi.nlm.nih.gov/pubmed/?term=30603552

Ethnicity

  1. Khadir A, Kavalakatt S, Dehbi M et al. DUSP1 Is a Potential Marker of Chronic Inflammation in Arabs with Cardiovascular Diseases. Disease markers 2018; 2018:9529621. http://www.ncbi.nlm.nih.gov/pubmed/?term=30647800
  2. Ramakumari N, Indumathi B, Katkam SK, Kutala VK. Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects. Indian Heart J 2018; 70 Suppl 3:S120-s125. http://www.ncbi.nlm.nih.gov/pubmed/?term=30595243
  3. Kanaya AM, Vittinghoff E, Lin F et al. Incidence and Progression of Coronary Artery Calcium in South Asians Compared With 4 Race/Ethnic Groups. J Am Heart Assoc 2019; 8:e011053. http://www.ncbi.nlm.nih.gov/pubmed/?term=30630376
  4. Khan R, Williams A, Dass DM et al. Investigating the risk of Incident diabetes mellitus among primary care patients treated with simvastatin in North-Central Trinidad. Journal of family medicine and primary care 2018; 7:1555-1560. http://www.ncbi.nlm.nih.gov/pubmed/?term=30613558

FH

  1. Elkins JC, Fruh S. Early diagnosis and treatment of familial hypercholesterolemia. The Nurse practitioner 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30614895
  2. Vuorio A, Watts GF, Kovanen PT. Lipoprotein(a) as a risk factor for calcific aortic valvulopathy in heterozygous familial hypercholesterolemia. Atherosclerosis 2018; 281:25-30. http://www.ncbi.nlm.nih.gov/pubmed/?term=30616181
  3. Miname MH, Bittencourt MS, Nasir K, Santos RD. Subclinical coronary atherosclerosis and cardiovascular risk stratification in heterozygous familial hypercholesterolemia patients undergoing statin treatment. Curr Opin Lipidol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30649025

Genetics

  1. Nelson CP, Lai FY, Nath M et al. Genetic Assessment of Potential Long-Term On-Target Side Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors. Circulation. Genomic and precision medicine 2019; 12:e002196. http://www.ncbi.nlm.nih.gov/pubmed/?term=30645167
  2. Bogari NM, Aljohani A, Amin AA et al. A genetic variant c.553G > T (rs2075291) in the apolipoprotein A5 gene is associated with altered triglycerides levels in coronary artery disease (CAD) patients with lipid lowering drug. BMC Cardiovasc Disord 2019; 19:2. http://www.ncbi.nlm.nih.gov/pubmed/?term=30606120
  3. Hynninen Y, Linna M, Vilkkumaa E. Value of genetic testing in the prevention of coronary heart disease events. PLoS One 2019; 14:e0210010. http://www.ncbi.nlm.nih.gov/pubmed/?term=30645616

Guidelines

  1. Dykun I, Wiefhoff D, Totzeck M et al. Disconcordance between ESC prevention guidelines and observed lipid profiles in patients with known coronary artery disease. International journal of cardiology. Heart & vasculature 2019; 22:73-77. http://www.ncbi.nlm.nih.gov/pubmed/?term=30603665
  2. Mosepele M, Regan S, Massaro J et al. Impact of the American College of Cardiology/American Heart Association Cholesterol Guidelines on Statin Eligibility Among Human Immunodeficiency Virus-Infected Individuals. Open Forum Infect Dis 2018; 5:ofy326. http://www.ncbi.nlm.nih.gov/pubmed/?term=30619912
  3. Gidlow CJ, Ellis NJ, Cowap L et al. A qualitative study of cardiovascular disease risk communication in NHS Health Check using different risk calculators: protocol for the RIsk COmmunication in NHS Health Check (RICO) study. BMC family practice 2019; 20:11. http://www.ncbi.nlm.nih.gov/pubmed/?term=30642267

LDL- related parameters

  1. Fan W, Song Y, Inzucchi SE et al. Composite Cardiovascular Risk Factor Target Achievement and its Predictors in US Adults with Diabetes: The Diabetes Collaborative Registry. Diabetes Obes Metab 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30609214
  2. Schettler VJJ, Muellendorff F, Schettler E et al. NMR-based lipoprotein analysis for patients with advanced hypercholesterolemia undergoing chronic lipoprotein apheresis or PCSK9-inhibitor therapy (NAPALI)-Study. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30663261
  3. Kumar M, Rehan HS, Puri R et al. Randomized controlled trial comparing the efficacy of daily and every other day atorvastatin therapy and its correlation with serum hydroxymethylglutaryl-CoA reductase enzyme levels in naive dyslipidemic patients. Indian Heart J 2018; 70 Suppl 3:S64-s67. http://www.ncbi.nlm.nih.gov/pubmed/?term=30595323
  4. Siddiqui MB, Arshad T, Patel S et al. Small Dense Low-Density Lipoprotein Cholesterol Predicts Cardiovascular Events In Liver Transplant Recipients. Hepatology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30672598
  5. Sorensen AL, Hasselbalch HC, Nielsen CH et al. Statin treatment, oxidative stress and inflammation in a Danish population. Redox biology 2018; 21:101088. http://www.ncbi.nlm.nih.gov/pubmed/?term=30594900

Lifestyle

  1. Qiu S, Cai X, Yang B et al. Association Between Cardiorespiratory Fitness and Risk of Type 2 Diabetes: A Meta-Analysis. Obesity (Silver Spring, Md.) 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30604925
  2. Molina-Sotomayor E, Arreguin-Moreno R, Rodriguez-Rodriguez F et al. [Effects of exercise on the cognition of older women treated with lovastatin]. Biomedica : revista del Instituto Nacional de Salud 2018; 38:496-506. http://www.ncbi.nlm.nih.gov/pubmed/?term=30653863

Meta-analyses

  1. Qiu S, Cai X, Yang B et al. Association Between Cardiorespiratory Fitness and Risk of Type 2 Diabetes: A Meta-Analysis. Obesity (Silver Spring, Md.) 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30604925
  2. Pirro M, Simental-Mendia LE, Bianconi V et al. Effect of Statin Therapy on Arterial Wall Inflammation Based on 18F-FDG PET/CT: A Systematic Review and Meta-Analysis of Interventional Studies. Journal of clinical medicine 2019; 8. http://www.ncbi.nlm.nih.gov/pubmed/?term=30669380
  3. Lu Y, Chang R, Yao J et al. Effectiveness of long-term using statins in COPD - a network meta-analysis. Respiratory research 2019; 20:17. http://www.ncbi.nlm.nih.gov/pubmed/?term=30674312
  4. Diamond DM, de Lorgeril M, Kendrick M et al. Formal comment on "Systematic review of the predictors of statin adherence for the primary prevention of cardiovascular disease". PLoS One 2019; 14:e0205138. http://www.ncbi.nlm.nih.gov/pubmed/?term=30653537
  5. Zhu XC, Dai WZ, Ma T. Overview the effect of statin therapy on dementia risk, cognitive changes and its pathologic change: a systematic review and meta-analysis. Annals of translational medicine 2018; 6:435. http://www.ncbi.nlm.nih.gov/pubmed/?term=30596065
  6. Ye Z, Lu H, Su Q et al. Short-term and long-term effects of a loading dose of atorvastatin before percutaneous coronary intervention on major adverse cardiovascular events in patients with acute coronary syndrome: a meta-analysis of 13 randomized controlled trials. Eur Heart J 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30608526
  7. Zhang Y, Liang M, Sun C et al. Statin Use and Risk of Pancreatic Cancer: An Updated Meta-analysis of 26 Studies. Pancreas 2019; 48:142-150. http://www.ncbi.nlm.nih.gov/pubmed/?term=30640225
  8. Zheng F, Liu M, Ye L et al. Statin use in patients undergoing carotid artery endarterectomy: still much to be uncovered. Acta neurochirurgica 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30648212
  9. Alves C, Mendes D, Batel Marques F. Statins and risk of cataracts: a systematic review and meta-analysis of observational studies. Cardiovasc Ther 2018:e12480. http://www.ncbi.nlm.nih.gov/pubmed/?term=30597753
  10. Hope HF, Binkley GM, Fenton S et al. Systematic review of the predictors of statin adherence for the primary prevention of cardiovascular disease. PLoS One 2019; 14:e0201196. http://www.ncbi.nlm.nih.gov/pubmed/?term=30653535

Metabolic Syndrome - Diabetes

  1. Kang EY, Chen TH, Garg SJ et al. Association of Statin Therapy With Prevention of Vision-Threatening Diabetic Retinopathy. JAMA ophthalmology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30629109
  2. Fan W, Song Y, Inzucchi SE et al. Composite Cardiovascular Risk Factor Target Achievement and its Predictors in US Adults with Diabetes: The Diabetes Collaborative Registry. Diabetes Obes Metab 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30609214
  3. Ma G, Bi S. Effect of rosuvastatin on vascular endothelial functions and inflammatory factors of patients with type 2 diabetes mellitus and coronary heart disease. Experimental and therapeutic medicine 2019; 17:332-336. http://www.ncbi.nlm.nih.gov/pubmed/?term=30651799
  4. Kameda A, Nakamura A, Kondo Y et al. Effects of switching to low-dose rosuvastatin (5 mg/day) on glucose metabolism and lipid profiles in Japanese patients with type 2 diabetes and dyslipidemia: a single-arm, prospective, interventional trial. Diabetology international 2017; 8:383-391. http://www.ncbi.nlm.nih.gov/pubmed/?term=30603344
  5. Eliasson L, Esguerra JLS, Wendt A. Lessons from basic pancreatic beta cell research in type-2 diabetes and vascular complications. Diabetology international 2017; 8:139-152. http://www.ncbi.nlm.nih.gov/pubmed/?term=30603317
  6. Biscetti F, Bonadia N, Santini F et al. Sortilin levels are associated with peripheral arterial disease in type 2 diabetic subjects. Cardiovascular diabetology 2019; 18:5. http://www.ncbi.nlm.nih.gov/pubmed/?term=30634965

New Treatments

  1. Kaufman TM, Warden BA, Minnier J et al. Application of PCSK9 Inhibitors in Practice. Circulation research 2019; 124:32-37. http://www.ncbi.nlm.nih.gov/pubmed/?term=30605414
  2. Nelson CP, Lai FY, Nath M et al. Genetic Assessment of Potential Long-Term On-Target Side Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors. Circulation. Genomic and precision medicine 2019; 12:e002196. http://www.ncbi.nlm.nih.gov/pubmed/?term=30645167
  3. Grabie M, Tai CH, Frishman WH. Is Anacetrapib Better Than Its CETP Inhibitor Counterparts? Cardiology in review 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30601160
  4. Schettler VJJ, Muellendorff F, Schettler E et al. NMR-based lipoprotein analysis for patients with advanced hypercholesterolemia undergoing chronic lipoprotein apheresis or PCSK9-inhibitor therapy (NAPALI)-Study. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30663261
  5. Moayedi Y, Kozuszko S, Knowles JW et al. Safety and Efficacy of PCSK9 Inhibitors After Heart Transplantation. Can J Cardiol 2019; 35:104.e101-104.e103. http://www.ncbi.nlm.nih.gov/pubmed/?term=30595172
  6. Koch CA, Krabbe S, Hehmke B. Statins, metformin, proprotein-convertase-subtilisin-kexin type-9 (PCSK9) inhibitors and sex hormones: Immunomodulatory properties? Reviews in endocrine & metabolic disorders 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30673921

Other

  1. Hira RS, Kataruka A, Akeroyd JM et al. Association of Body Mass Index With Risk Factor Optimization and Guideline-Directed Medical Therapy in US Veterans With Cardiovascular Disease. Circ Cardiovasc Qual Outcomes 2019; 12:e004817. http://www.ncbi.nlm.nih.gov/pubmed/?term=30636483
  2. Patel MS, Kurtzman GW, Kannan S et al. Effect of an Automated Patient Dashboard Using Active Choice and Peer Comparison Performance Feedback to Physicians on Statin Prescribing: The PRESCRIBE Cluster Randomized Clinical Trial. JAMA network open 2018; 1:e180818. http://www.ncbi.nlm.nih.gov/pubmed/?term=30646039
  3. Zhou Y, Yao X, Liu G et al. Level and variation on quality of care in China: a cross-sectional study for the acute myocardial infarction patients in tertiary hospitals in Beijing. BMC Health Serv Res 2019; 19:43. http://www.ncbi.nlm.nih.gov/pubmed/?term=30658628
  4. Doshi P, Sieluk J, Hung A. The possible harms of statins: What do product labels, patient package inserts, and pharmacy leaflets tell us? Journal of the American Pharmacists Association : JAPhA 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30661956
  5. Sarpatwari A, Gagne JJ, Lu Z et al. A Survey of Patients' Perceptions of Pill Appearance and Responses to Changes in Appearance for Four Chronic Disease Medications. Journal of general internal medicine 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30632102

PAD and statins

  1. Biscetti F, Bonadia N, Santini F et al. Sortilin levels are associated with peripheral arterial disease in type 2 diabetic subjects. Cardiovascular diabetology 2019; 18:5. http://www.ncbi.nlm.nih.gov/pubmed/?term=30634965

Pleiotropic effects of statins

  1. Zhang ZZ, Zhang HZ, Zhang ZY. 3D printed poly(epsilon-caprolactone) scaffolds function with simvastatin-loaded poly(lactic-co-glycolic acid) microspheres to repair load-bearing segmental bone defects. Experimental and therapeutic medicine 2019; 17:79-90. http://www.ncbi.nlm.nih.gov/pubmed/?term=30651767
  2. Carrer A, Trefely S, Zhao S et al. Acetyl-CoA metabolism supports multi-step pancreatic tumorigenesis. Cancer discovery 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30626590
  3. Menon S, Mathew R. Association between metabolic syndrome and hepatobiliary cancers: A case-control study. Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30628006
  4. Kang EY, Chen TH, Garg SJ et al. Association of Statin Therapy With Prevention of Vision-Threatening Diabetic Retinopathy. JAMA ophthalmology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30629109
  5. Matsuo K, Hom MS, Yabuno A et al. Association of statins, aspirin, and venous thromboembolism in women with endometrial cancer. Gynecologic oncology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30616901
  6. An L, An S, Jia Z et al. Atorvastatin improves left ventricular remodeling and cardiac function in rats with congestive heart failure by inhibiting RhoA/Rho kinase-mediated endothelial nitric oxide synthase. Experimental and therapeutic medicine 2019; 17:960-966. http://www.ncbi.nlm.nih.gov/pubmed/?term=30651887
  7. Fang T, Guo B, Xue L, Wang L. Atorvastatin Prevents Myocardial Fibrosis in Spontaneous Hypertension via Interleukin-6 (IL-6)/Signal Transducer and Activator of Transcription 3 (STAT3)/Endothelin-1 (ET-1) Pathway. Medical science monitor : international medical journal of experimental and clinical research 2019; 25:318-323. http://www.ncbi.nlm.nih.gov/pubmed/?term=30631031
  8. Tanaka T, Matsushita T, Nishida K et al. Attenuation of osteoarthritis progression in mice following intra-articular administration of simvastatin-conjugated gelatin hydrogel. Journal of tissue engineering and regenerative medicine 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30644168
  9. Jamil A, Mirza MA, Anwer K et al. Co-delivery of Gemcitabine and Simvastatin through PLGA polymeric nanoparticles for thetreatment of pancreatic cancer: In-vitro characterization, cellular uptake and pharmacokinetic studies. Drug development and industrial pharmacy 2019:1-34. http://www.ncbi.nlm.nih.gov/pubmed/?term=30632800
  10. Ma G, Bi S. Effect of rosuvastatin on vascular endothelial functions and inflammatory factors of patients with type 2 diabetes mellitus and coronary heart disease. Experimental and therapeutic medicine 2019; 17:332-336. http://www.ncbi.nlm.nih.gov/pubmed/?term=30651799
  11. Lu Y, Chang R, Yao J et al. Effectiveness of long-term using statins in COPD - a network meta-analysis. Respiratory research 2019; 20:17. http://www.ncbi.nlm.nih.gov/pubmed/?term=30674312
  12. Kaplan DE, Serper M, Mehta R et al. Effects of Hypercholesterolemia and Statin Exposure on Survival in a Large National Cohort of Patients With Cirrhosis. Gastroenterology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30660733
  13. Chen Y, Li X, Zhang R et al. Effects of statin exposure and lung cancer survival: A meta-analysis of observational studies. Pharmacol Res 2019; 141:357-365. http://www.ncbi.nlm.nih.gov/pubmed/?term=30641276
  14. Zhao WB, Fu H, Chang F et al. Effects of various doses of atorvastatin on vascular endothelial cell apoptosis and autophagy in vitro. Mol Med Rep 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30628690
  15. El-Refai SM, Brown JD, Arnold SM et al. Epidemiologic Analysis Along the Mevalonate Pathway Reveals Improved Cancer Survival in Patients Who Receive Statins Alone and in Combination With Bisphosphonates. JCO clinical cancer informatics 2017; 1:1-12. http://www.ncbi.nlm.nih.gov/pubmed/?term=30657380
  16. Kim TH, Yun YP, Shim KS et al. In Vitro Anti-Inflammation and Chondrogenic Differentiation Effects of Inclusion Nanocomplexes of Hyaluronic Acid-Beta Cyclodextrin and Simvastatin. Tissue engineering and regenerative medicine 2018; 15:263-274. http://www.ncbi.nlm.nih.gov/pubmed/?term=30603552
  17. Zheng XF, Liu KX, Wang XM et al. MicroRNA192 acts as a tumor suppressor in colon cancer and simvastatin activates miR192 to inhibit cancer cell growth. Mol Med Rep 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30628692
  18. de Faria CA, Zanette DL, Silva WA, Jr., Ribeiro-Paes JT. PAI-1 inhibition by simvastatin as a positive adjuvant in cell therapy. Molecular biology reports 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30612281
  19. Joentausta RM, Rannikko A, Murtola TJ. Prostate cancer survival among statin users after prostatectomy in a Finnish nationwide cohort. Prostate 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30652328
  20. Aktay G, Gursoy SO, Uyumlu U et al. Protective effect of atorvastatin on oxidative stress in streptozotocin-induced diabetic rats independently their lipid-lowering effects. Journal of biochemical and molecular toxicology 2019:e22295. http://www.ncbi.nlm.nih.gov/pubmed/?term=30657622
  21. Encarnacao IC, Sordi MB, Aragones A et al. Release of simvastatin from scaffolds of poly(lactic-co-glycolic) acid and biphasic ceramic designed for bone tissue regeneration. Journal of biomedical materials research. Part B, Applied biomaterials 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30653823
  22. Raafat SN. Response to letter to the editor: The sole and combined effect of simvastatin and platelet rich fibrin as a filling material in induced bone defect in tibia of albino rats. Bone 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30612981
  23. El-Korashi LA, Soliman MH, Attwa EM, Mohamed NA. Role of Atorvastatin in Treatment of Chronic Spontaneous Urticaria Patients: A Controlled Clinical Trial. The Egyptian journal of immunology 2018; 25:133-139. http://www.ncbi.nlm.nih.gov/pubmed/?term=30600956
  24. Doumas M, Imprialos K, Dimakopoulou A et al. The role of statins in the management of nonalcoholic fatty liver disease. Current pharmaceutical design 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30652643
  25. Zhang J, Shi X, Hao N et al. Simvastatin Reduces Neutrophils Infiltration Into Brain Parenchyma After Intracerebral Hemorrhage via Regulating Peripheral Neutrophils Apoptosis. Frontiers in neuroscience 2018; 12:977. http://www.ncbi.nlm.nih.gov/pubmed/?term=30631264
  26. Sui Z, Wang M, Zuo L. Statin therapy and erythropoiesis-stimulating agent hyporesponsiveness in patients with nondialysis chronic kidney disease: A retrospective study in Beijing, China. Medicine (Baltimore) 2019; 98:e13981. http://www.ncbi.nlm.nih.gov/pubmed/?term=30633179
  27. Hsu C, Brahmandam A, Brownson KE et al. Statin therapy associated with improved thrombus resolution in patients with deep vein thrombosis. Journal of vascular surgery. Venous and lymphatic disorders 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30660579
  28. Kohler-Forsberg O, Gasse C, Petersen L et al. Statin treatment and the risk of depression. Journal of affective disorders 2018; 246:706-715. http://www.ncbi.nlm.nih.gov/pubmed/?term=30611914
  29. Sorensen AL, Hasselbalch HC, Nielsen CH et al. Statin treatment, oxidative stress and inflammation in a Danish population. Redox biology 2018; 21:101088. http://www.ncbi.nlm.nih.gov/pubmed/?term=30594900
  30. Thrift AP, Natarajan Y, Liu Y, El-Serag HB. Statin use after diagnosis of hepatocellular carcinoma and patient survival: findings from a retrospective cohort study. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30625400
  31. Zhang Y, Liang M, Sun C et al. Statin Use and Risk of Pancreatic Cancer: An Updated Meta-analysis of 26 Studies. Pancreas 2019; 48:142-150. http://www.ncbi.nlm.nih.gov/pubmed/?term=30640225
  32. Omori M, Okuma Y, Hakozaki T, Hosomi Y. Statins improve survival in patients previously treated with nivolumab for advanced non-small cell lung cancer: An observational study. Molecular and clinical oncology 2019; 10:137-143. http://www.ncbi.nlm.nih.gov/pubmed/?term=30655989
  33. Lanzillo R, Moccia M, Russo CV et al. Therapeutic lag in reducing disability progression in relapsing-remitting multiple sclerosis: 8-year follow-up of two randomized add-on trials with atorvastatin. Multiple sclerosis and related disorders 2019; 28:193-196. http://www.ncbi.nlm.nih.gov/pubmed/?term=30623857
  34. Chen YT, Kuo SC, Chao PW, Chang YY. Use of lipid-lowering agents is not associated with improved outcomes for tuberculosis patients on standard-course therapy: A population-based cohort study. PLoS One 2019; 14:e0210479. http://www.ncbi.nlm.nih.gov/pubmed/?term=30633771

Primary Prevention

  1. Diamond DM, de Lorgeril M, Kendrick M et al. Formal comment on "Systematic review of the predictors of statin adherence for the primary prevention of cardiovascular disease". PLoS One 2019; 14:e0205138. http://www.ncbi.nlm.nih.gov/pubmed/?term=30653537
  2. Hope HF, Binkley GM, Fenton S et al. Systematic review of the predictors of statin adherence for the primary prevention of cardiovascular disease. PLoS One 2019; 14:e0201196. http://www.ncbi.nlm.nih.gov/pubmed/?term=30653535

Registry data

  1. Colantonio LD, Rosenson RS, Deng L et al. Adherence to Statin Therapy Among US Adults Between 2007 and 2014. J Am Heart Assoc 2019; 8:e010376. http://www.ncbi.nlm.nih.gov/pubmed/?term=30616455
  2. Gill SS. All, some or none? Statin prescribing for frail older adults. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2019; 191:E30-e31. http://www.ncbi.nlm.nih.gov/pubmed/?term=30642822
  3. Kaufman TM, Warden BA, Minnier J et al. Application of PCSK9 Inhibitors in Practice. Circulation research 2019; 124:32-37. http://www.ncbi.nlm.nih.gov/pubmed/?term=30605414
  4. Khunti K, Danese MD, Kutikova L et al. Association of a Combined Measure of Adherence and Treatment Intensity With Cardiovascular Outcomes in Patients With Atherosclerosis or Other Cardiovascular Risk Factors Treated With Statins and/or Ezetimibe. JAMA network open 2018; 1:e185554. http://www.ncbi.nlm.nih.gov/pubmed/?term=30646277
  5. Hira RS, Kataruka A, Akeroyd JM et al. Association of Body Mass Index With Risk Factor Optimization and Guideline-Directed Medical Therapy in US Veterans With Cardiovascular Disease. Circ Cardiovasc Qual Outcomes 2019; 12:e004817. http://www.ncbi.nlm.nih.gov/pubmed/?term=30636483
  6. Lowenstern A, Navar AM, Li S et al. Association of Clinician Knowledge and Statin Beliefs With Statin Therapy Use and Lipid Levels (A Survey of US Practice in the PALM Registry). Am J Cardiol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30660354
  7. Matsuo K, Hom MS, Yabuno A et al. Association of statins, aspirin, and venous thromboembolism in women with endometrial cancer. Gynecologic oncology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30616901
  8. Rasmussen DB, Bodtger U, Lamberts M et al. Beta-blocker, aspirin and statin usage after first-time myocardial infarction in patients with chronicAuthor information obstructive pulmonary disease: a nationwide analysis from 1995 to 2015 in Denmark. European heart journal. Quality of care & clinical outcomes 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30608575
  9. De Luca L, Luigi Temporelli P, Riccio C et al. Clinical Outcomes, Pharmacologic Treatment and Quality of Life of Patients with Stable Coronary Artery Diseases Managed by Cardiologists: 1-Year Results of the START Study. European heart journal. Quality of care & clinical outcomes 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30649303
  10. Song S, Liang L, Fonarow GC et al. Comparison of Clinical Care and In-Hospital Outcomes of Asian American and White Patients With Acute Ischemic Stroke. JAMA neurology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30667466
  11. Fan W, Song Y, Inzucchi SE et al. Composite Cardiovascular Risk Factor Target Achievement and its Predictors in US Adults with Diabetes: The Diabetes Collaborative Registry. Diabetes Obes Metab 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30609214
  12. Nannoni S, Sirimarco G, Cereda CW et al. Determining factors of better leptomeningeal collaterals: a study of 857 consecutive acute ischemic stroke patients. Journal of neurology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30610425
  13. Khadir A, Kavalakatt S, Dehbi M et al. DUSP1 Is a Potential Marker of Chronic Inflammation in Arabs with Cardiovascular Diseases. Disease markers 2018; 2018:9529621. http://www.ncbi.nlm.nih.gov/pubmed/?term=30647800
  14. Kaplan DE, Serper M, Mehta R et al. Effects of Hypercholesterolemia and Statin Exposure on Survival in a Large National Cohort of Patients With Cirrhosis. Gastroenterology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30660733
  15. Chen Y, Li X, Zhang R et al. Effects of statin exposure and lung cancer survival: A meta-analysis of observational studies. Pharmacol Res 2019; 141:357-365. http://www.ncbi.nlm.nih.gov/pubmed/?term=30641276
  16. El-Refai SM, Brown JD, Arnold SM et al. Epidemiologic Analysis Along the Mevalonate Pathway Reveals Improved Cancer Survival in Patients Who Receive Statins Alone and in Combination With Bisphosphonates. JCO clinical cancer informatics 2017; 1:1-12. http://www.ncbi.nlm.nih.gov/pubmed/?term=30657380
  17. Fan W, Philip S, Granowitz C et al. Hypertriglyceridemia in statin-treated US adults: the National Health and Nutrition Examination Survey. J Clin Lipidol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30594443
  18. Ramakumari N, Indumathi B, Katkam SK, Kutala VK. Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects. Indian Heart J 2018; 70 Suppl 3:S120-s125. http://www.ncbi.nlm.nih.gov/pubmed/?term=30595243
  19. Kanaya AM, Vittinghoff E, Lin F et al. Incidence and Progression of Coronary Artery Calcium in South Asians Compared With 4 Race/Ethnic Groups. J Am Heart Assoc 2019; 8:e011053. http://www.ncbi.nlm.nih.gov/pubmed/?term=30630376
  20. Khan R, Williams A, Dass DM et al. Investigating the risk of Incident diabetes mellitus among primary care patients treated with simvastatin in North-Central Trinidad. Journal of family medicine and primary care 2018; 7:1555-1560. http://www.ncbi.nlm.nih.gov/pubmed/?term=30613558
  21. Chen JF, Smilowitz NR, Kim JT et al. Medical therapy for atherosclerotic cardiovascular disease in patients with myocardial injury after non-cardiac surgery. Int J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30598249
  22. Campitelli MA, Maxwell CJ, Maclagan LC et al. One-year survival and admission to hospital for cardiovascular events among older residents of long-term care facilities who were prescribed intensive- and moderate-dose statins. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2019; 191:E32-e39. http://www.ncbi.nlm.nih.gov/pubmed/?term=30642823
  23. van der Ploeg MA, Streit S, Achterberg WP et al. Patient Characteristics and General Practitioners' Advice to Stop Statins in Oldest-Old Patients: a Survey Study Across 30 Countries. Journal of general internal medicine 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30652277
  24. Joentausta RM, Rannikko A, Murtola TJ. Prostate cancer survival among statin users after prostatectomy in a Finnish nationwide cohort. Prostate 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30652328
  25. Bezin J, Moore N, Mansiaux Y et al. Real-life benefits of statins for cardiovascular prevention in elderly subjects: a population-based cohort study. Am J Med 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30660573
  26. Sui Z, Wang M, Zuo L. Statin therapy and erythropoiesis-stimulating agent hyporesponsiveness in patients with nondialysis chronic kidney disease: A retrospective study in Beijing, China. Medicine (Baltimore) 2019; 98:e13981. http://www.ncbi.nlm.nih.gov/pubmed/?term=30633179
  27. Hsu C, Brahmandam A, Brownson KE et al. Statin therapy associated with improved thrombus resolution in patients with deep vein thrombosis. Journal of vascular surgery. Venous and lymphatic disorders 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30660579
  28. Kohler-Forsberg O, Gasse C, Petersen L et al. Statin treatment and the risk of depression. Journal of affective disorders 2018; 246:706-715. http://www.ncbi.nlm.nih.gov/pubmed/?term=30611914
  29. Thrift AP, Natarajan Y, Liu Y, El-Serag HB. Statin use after diagnosis of hepatocellular carcinoma and patient survival: findings from a retrospective cohort study. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30625400
  30. Borgquist S, Broberg P, Tojjar J, Olsson H. Statin use and breast cancer survival - a Swedish nationwide study. BMC Cancer 2019; 19:54. http://www.ncbi.nlm.nih.gov/pubmed/?term=30634941

Renal Disease

  1. Streja E, Gosmanova EO, Molnar MZ et al. Association of Continuation of Statin Therapy Initiated Before Transition to Chronic Dialysis Therapy With Mortality After Dialysis Initiation. JAMA network open 2018; 1:e182311. http://www.ncbi.nlm.nih.gov/pubmed/?term=30646217
  2. Sui Z, Wang M, Zuo L. Statin therapy and erythropoiesis-stimulating agent hyporesponsiveness in patients with nondialysis chronic kidney disease: A retrospective study in Beijing, China. Medicine (Baltimore) 2019; 98:e13981. http://www.ncbi.nlm.nih.gov/pubmed/?term=30633179
  3. Seo JH, Chun KJ, Lee BK et al. Statins Have No Role in Preventing the Progression of Aortic Valve Sclerosis. Journal of cardiovascular imaging 2018; 26:229-237. http://www.ncbi.nlm.nih.gov/pubmed/?term=30607391
  4. Mefford MT, Rosenson RS, Deng L et al. Trends in Statin Use Among US Adults With Chronic Kidney Disease, 1999-2014. J Am Heart Assoc 2019; 8:e010640. http://www.ncbi.nlm.nih.gov/pubmed/?term=30651020

Reviews

  1. Larsen LE, Stoekenbroek RM, Kastelein JJP, Holleboom AG. Moving Targets. Arterioscler Thromb Vasc Biol 2019:Atvbaha118312028. http://www.ncbi.nlm.nih.gov/pubmed/?term=30676072
  2. Anquetil C, Boyer O, Wesner N et al. Review: Myositis-specific autoantibodies, a cornerstone in immune-mediated necrotizing myopathy. Autoimmunity reviews 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30639649
  3. Grabie M, Tai CH, Frishman WH. Is Anacetrapib Better Than Its CETP Inhibitor Counterparts? Cardiology in review 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30601160
  4. Kaufman TM, Warden BA, Minnier J et al. Application of PCSK9 Inhibitors in Practice. Circulation research 2019; 124:32-37. http://www.ncbi.nlm.nih.gov/pubmed/?term=30605414
  5. Ward NC, Watts GF, Eckel RH. Statin Toxicity. Circulation research 2019; 124:328-350. http://www.ncbi.nlm.nih.gov/pubmed/?term=30653440
  6. Preston Mason R. New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease. Curr Atheroscler Rep 2019; 21:2. http://www.ncbi.nlm.nih.gov/pubmed/?term=30637567
  7. Doumas M, Imprialos K, Dimakopoulou A et al. The role of statins in the management of nonalcoholic fatty liver disease. Current pharmaceutical design 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30652643
  8. Reklou A, Katsiki N, Karagiannis A, Athyros V. Effects of lipid lowering drugs on arterial stiffness. One more way to reduce cardiovascular risk? Current vascular pharmacology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30663570
  9. Eliasson L, Esguerra JLS, Wendt A. Lessons from basic pancreatic beta cell research in type-2 diabetes and vascular complications. Diabetology international 2017; 8:139-152. http://www.ncbi.nlm.nih.gov/pubmed/?term=30603317
  10. Yandrapalli S, Gupta S, Andries G et al. Drug Therapy of Dyslipidemia in the Elderly. Drugs Aging 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30613912
  11. Nixdorff U, Horstick G, Schlitt A. [Acute coronary syndrome : Prevention]. Herz 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30671595
  12. Dykun I, Wiefhoff D, Totzeck M et al. Disconcordance between ESC prevention guidelines and observed lipid profiles in patients with known coronary artery disease. International journal of cardiology. Heart & vasculature 2019; 22:73-77. http://www.ncbi.nlm.nih.gov/pubmed/?term=30603665
  13. Mefford MT, Rosenson RS, Deng L et al. Trends in Statin Use Among US Adults With Chronic Kidney Disease, 1999-2014. J Am Heart Assoc 2019; 8:e010640. http://www.ncbi.nlm.nih.gov/pubmed/?term=30651020
  14. Alonso R, Cuevas A, Cafferata A. Diagnosis and Management of Statin Intolerance. J Atheroscler Thromb 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30662020
  15. Hynninen Y, Linna M, Vilkkumaa E. Value of genetic testing in the prevention of coronary heart disease events. PLoS One 2019; 14:e0210010. http://www.ncbi.nlm.nih.gov/pubmed/?term=30645616
  16. Koch CA, Krabbe S, Hehmke B. Statins, metformin, proprotein-convertase-subtilisin-kexin type-9 (PCSK9) inhibitors and sex hormones: Immunomodulatory properties? Reviews in endocrine & metabolic disorders 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30673921
  17. Almeida SO, Budoff M. Effect of statins on atherosclerotic plaque. Trends Cardiovasc Med 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30642643
  18. Pitha J, Topinkova E, Blaha V et al. Statin therapy in elderly patients. Vnitr Lek 2018; 64:1021-1027. http://www.ncbi.nlm.nih.gov/pubmed/?term=30606018

Safety and side effects

  1. Anquetil C, Boyer O, Wesner N et al. Review: Myositis-specific autoantibodies, a cornerstone in immune-mediated necrotizing myopathy. Autoimmunity reviews 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30639649
  2. Takahashi T, Uno Y, Yamazaki H, Kume T. Functional characterization for polymorphic organic anion transporting polypeptides (OATP/SLCO1B1, 1B3, 2B1) of monkeys recombinantly expressed with various OATP probes. Biopharmaceutics & drug disposition 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30652318
  3. Alves C, Mendes D, Batel Marques F. Statins and risk of cataracts: a systematic review and meta-analysis of observational studies. Cardiovasc Ther 2018:e12480. http://www.ncbi.nlm.nih.gov/pubmed/?term=30597753
  4. Nelson CP, Lai FY, Nath M et al. Genetic Assessment of Potential Long-Term On-Target Side Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors. Circulation. Genomic and precision medicine 2019; 12:e002196. http://www.ncbi.nlm.nih.gov/pubmed/?term=30645167
  5. Ward NC, Watts GF, Eckel RH. Statin Toxicity. Circulation research 2019; 124:328-350. http://www.ncbi.nlm.nih.gov/pubmed/?term=30653440
  6. Wasko JA, Dietrich E, Davis K. Risk of Daptomycin Associated Myopathy with Concomitant Statin Use. Clin Infect Dis 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30596967
  7. Ronnqvist J, Hallberg P, Yue QY, Wadelius M. Fusidic Acid: A Neglected Risk Factor for Statin-Associated Myopathy. Clinical Medicine Insights. Cardiology 2018; 12:1179546818815162. http://www.ncbi.nlm.nih.gov/pubmed/?term=30618488
  8. Eliasson L, Esguerra JLS, Wendt A. Lessons from basic pancreatic beta cell research in type-2 diabetes and vascular complications. Diabetology international 2017; 8:139-152. http://www.ncbi.nlm.nih.gov/pubmed/?term=30603317
  9. Kameda A, Nakamura A, Kondo Y et al. Effects of switching to low-dose rosuvastatin (5 mg/day) on glucose metabolism and lipid profiles in Japanese patients with type 2 diabetes and dyslipidemia: a single-arm, prospective, interventional trial. Diabetology international 2017; 8:383-391. http://www.ncbi.nlm.nih.gov/pubmed/?term=30603344
  10. Agrawal D, Manchanda SC, Sawhney JPS et al. To study the effect of high dose Atorvastatin 40mg versus 80mg in patients with dyslipidemia. Indian Heart J 2018; 70 Suppl 3:S8-s12. http://www.ncbi.nlm.nih.gov/pubmed/?term=30595326
  11. Ramakumari N, Indumathi B, Katkam SK, Kutala VK. Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects. Indian Heart J 2018; 70 Suppl 3:S120-s125. http://www.ncbi.nlm.nih.gov/pubmed/?term=30595243
  12. Doshi P, Sieluk J, Hung A. The possible harms of statins: What do product labels, patient package inserts, and pharmacy leaflets tell us? Journal of the American Pharmacists Association : JAPhA 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30661956
  13. Alonso R, Cuevas A, Cafferata A. Diagnosis and Management of Statin Intolerance. J Atheroscler Thromb 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30662020
  14. Naz S, Saleem MW, Haider AW. Angioedema; An Unreported Adverse Effect Of Pitavastatin. Journal of Ayub Medical College, Abbottabad : JAMC 2018; 30:603-604. http://www.ncbi.nlm.nih.gov/pubmed/?term=30632346
  15. Paseban M, Butler AE, Sahebkar A. Mechanisms of statin-induced new-onset diabetes. Journal of cellular physiology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30618154
  16. Khan R, Williams A, Dass DM et al. Investigating the risk of Incident diabetes mellitus among primary care patients treated with simvastatin in North-Central Trinidad. Journal of family medicine and primary care 2018; 7:1555-1560. http://www.ncbi.nlm.nih.gov/pubmed/?term=30613558
  17. Qiu S, Cai X, Yang B et al. Association Between Cardiorespiratory Fitness and Risk of Type 2 Diabetes: A Meta-Analysis. Obesity (Silver Spring, Md.) 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30604925
  18. Beverly BEJ, Furr JR, Lambright CS et al. In utero exposure to simvastatin reduces postnatal survival and permanently alters reproductive tract development in the Crl:CD(SD) male rat. Toxicology and applied pharmacology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30639414

Stroke and CNS

  1. Ironside N, Brenner D, Heyer E et al. In response to letter to the editor "Statin use in patients undergoing carotid artery endarterectomy: still much to be uncovered". Acta neurochirurgica 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30666454
  2. Zheng F, Liu M, Ye L et al. Statin use in patients undergoing carotid artery endarterectomy: still much to be uncovered. Acta neurochirurgica 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30648212
  3. Zhu XC, Dai WZ, Ma T. Overview the effect of statin therapy on dementia risk, cognitive changes and its pathologic change: a systematic review and meta-analysis. Annals of translational medicine 2018; 6:435. http://www.ncbi.nlm.nih.gov/pubmed/?term=30596065
  4. Zhang J, Shi X, Hao N et al. Simvastatin Reduces Neutrophils Infiltration Into Brain Parenchyma After Intracerebral Hemorrhage via Regulating Peripheral Neutrophils Apoptosis. Frontiers in neuroscience 2018; 12:977. http://www.ncbi.nlm.nih.gov/pubmed/?term=30631264
  5. Nannoni S, Sirimarco G, Cereda CW et al. Determining factors of better leptomeningeal collaterals: a study of 857 consecutive acute ischemic stroke patients. Journal of neurology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30610425
  6. Song S, Liang L, Fonarow GC et al. Comparison of Clinical Care and In-Hospital Outcomes of Asian American and White Patients With Acute Ischemic Stroke. JAMA neurology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30667466
  7. Lanzillo R, Moccia M, Russo CV et al. Therapeutic lag in reducing disability progression in relapsing-remitting multiple sclerosis: 8-year follow-up of two randomized add-on trials with atorvastatin. Multiple sclerosis and related disorders 2019; 28:193-196. http://www.ncbi.nlm.nih.gov/pubmed/?term=30623857
  8. Rizwan M, Aridi HD, Dang T et al. Long-Term Outcomes of Carotid Endarterectomy and Carotid Artery Stenting When Performed by a Single Vascular Surgeon. Vascular and endovascular surgery 2019:1538574418823379. http://www.ncbi.nlm.nih.gov/pubmed/?term=30614413

Triglycerides/HDL

  1. Bogari NM, Aljohani A, Amin AA et al. A genetic variant c.553G > T (rs2075291) in the apolipoprotein A5 gene is associated with altered triglycerides levels in coronary artery disease (CAD) patients with lipid lowering drug. BMC Cardiovasc Disord 2019; 19:2. http://www.ncbi.nlm.nih.gov/pubmed/?term=30606120
  2. Chaudhary R, Kinderyte M, Chaudhary R et al. HDL3-C is a marker of coronary artery disease severity and inflammation in patients on statin therapy. Cardiovascular revascularization medicine : including molecular interventions 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30626544
  3. Najafipour M, Zareizadeh M, Khokhi MA, Najafipour F. Comparative study of the effect of atorvastatin and fenofibrate on high-density lipoprotein cholesterol levels in patients with type 2 diabetes. Journal of advanced pharmaceutical technology & research 2018; 9:135-138. http://www.ncbi.nlm.nih.gov/pubmed/?term=30637231
  4. Fan W, Philip S, Granowitz C et al. Hypertriglyceridemia in statin-treated US adults: the National Health and Nutrition Examination Survey. J Clin Lipidol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30594443

Trials

  1. Kazi DS, Penko J, Coxson PG et al. Cost-Effectiveness of Alirocumab: A Just-in-Time Analysis Based on the ODYSSEY Outcomes Trial. Annals of internal medicine 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30597485
  2. Gidlow CJ, Ellis NJ, Cowap L et al. A qualitative study of cardiovascular disease risk communication in NHS Health Check using different risk calculators: protocol for the RIsk COmmunication in NHS Health Check (RICO) study. BMC family practice 2019; 20:11. http://www.ncbi.nlm.nih.gov/pubmed/?term=30642267
  3. Moayedi Y, Kozuszko S, Knowles JW et al. Safety and Efficacy of PCSK9 Inhibitors After Heart Transplantation. Can J Cardiol 2019; 35:104.e101-104.e103. http://www.ncbi.nlm.nih.gov/pubmed/?term=30595172
  4. Chaudhary R, Kinderyte M, Chaudhary R et al. HDL3-C is a marker of coronary artery disease severity and inflammation in patients on statin therapy. Cardiovascular revascularization medicine : including molecular interventions 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30626544
  5. Navar AM, Roe MT, White JA et al. Medication Discontinuation in the IMPROVE-IT Trial. Circ Cardiovasc Qual Outcomes 2019; 12:e005041. http://www.ncbi.nlm.nih.gov/pubmed/?term=30630361
  6. Hong SJ, Jeong HS, Cho JM et al. Efficacy and Safety of Triple Therapy With Telmisartan, Amlodipine, and Rosuvastatin in Patients With Dyslipidemia and Hypertension: The Jeil Telmisartan, Amlodipine, and Rosuvastatin Randomized Clinical Trial. Clinical therapeutics 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30665829
  7. Devaraj S, Siegel D, Jialal I. Correction to: Statin Therapy in Metabolic Syndrome and Hypertension Post-JUPITER: What is the Value of CRP? Curr Atheroscler Rep 2019; 21:3. http://www.ncbi.nlm.nih.gov/pubmed/?term=30662999
  8. Kameda A, Nakamura A, Kondo Y et al. Effects of switching to low-dose rosuvastatin (5 mg/day) on glucose metabolism and lipid profiles in Japanese patients with type 2 diabetes and dyslipidemia: a single-arm, prospective, interventional trial. Diabetology international 2017; 8:383-391. http://www.ncbi.nlm.nih.gov/pubmed/?term=30603344
  9. El-Korashi LA, Soliman MH, Attwa EM, Mohamed NA. Role of Atorvastatin in Treatment of Chronic Spontaneous Urticaria Patients: A Controlled Clinical Trial. The Egyptian journal of immunology 2018; 25:133-139. http://www.ncbi.nlm.nih.gov/pubmed/?term=30600956
  10. Lamy A, Lonn E, Tong W et al. The cost implication of primary prevention in the HOPE 3 trial. European heart journal. Quality of care & clinical outcomes 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30657891
  11. Ma G, Bi S. Effect of rosuvastatin on vascular endothelial functions and inflammatory factors of patients with type 2 diabetes mellitus and coronary heart disease. Experimental and therapeutic medicine 2019; 17:332-336. http://www.ncbi.nlm.nih.gov/pubmed/?term=30651799
  12. Siddiqui MB, Arshad T, Patel S et al. Small Dense Low-Density Lipoprotein Cholesterol Predicts Cardiovascular Events In Liver Transplant Recipients. Hepatology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30672598
  13. Agrawal D, Manchanda SC, Sawhney JPS et al. To study the effect of high dose Atorvastatin 40mg versus 80mg in patients with dyslipidemia. Indian Heart J 2018; 70 Suppl 3:S8-s12. http://www.ncbi.nlm.nih.gov/pubmed/?term=30595326
  14. Kumar M, Rehan HS, Puri R et al. Randomized controlled trial comparing the efficacy of daily and every other day atorvastatin therapy and its correlation with serum hydroxymethylglutaryl-CoA reductase enzyme levels in naive dyslipidemic patients. Indian Heart J 2018; 70 Suppl 3:S64-s67. http://www.ncbi.nlm.nih.gov/pubmed/?term=30595323
  15. Menon S, Mathew R. Association between metabolic syndrome and hepatobiliary cancers: A case-control study. Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30628006
  16. Pourhosseini H, Lashkari R, Aminorroaya A et al. Effects of high dose atorvastatin before elective percutaneous coronary intervention on highly sensitive troponin T and one year major cardiovascular events; a randomized clinical trial. International journal of cardiology. Heart & vasculature 2019; 22:96-101. http://www.ncbi.nlm.nih.gov/pubmed/?term=30671535
  17. Najafipour M, Zareizadeh M, Khokhi MA, Najafipour F. Comparative study of the effect of atorvastatin and fenofibrate on high-density lipoprotein cholesterol levels in patients with type 2 diabetes. Journal of advanced pharmaceutical technology & research 2018; 9:135-138. http://www.ncbi.nlm.nih.gov/pubmed/?term=30637231
  18. Doshi P, Sieluk J, Hung A. The possible harms of statins: What do product labels, patient package inserts, and pharmacy leaflets tell us? Journal of the American Pharmacists Association : JAPhA 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30661956
  19. Nabati M, Janbabai G, Esmailian J, Yazdani J. Effect of Rosuvastatin in Preventing Chemotherapy-Induced Cardiotoxicity in Women With Breast Cancer: A Randomized, Single-Blind, Placebo-Controlled Trial. Journal of cardiovascular pharmacology and therapeutics 2019:1074248418821721. http://www.ncbi.nlm.nih.gov/pubmed/?term=30599756
  20. Peverelle MR, Baradi A, Paleri S et al. Higher long-term adherence to statins in rural patients at high atherosclerotic risk. J Clin Lipidol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30594444
  21. Patel MS, Kurtzman GW, Kannan S et al. Effect of an Automated Patient Dashboard Using Active Choice and Peer Comparison Performance Feedback to Physicians on Statin Prescribing: The PRESCRIBE Cluster Randomized Clinical Trial. JAMA network open 2018; 1:e180818. http://www.ncbi.nlm.nih.gov/pubmed/?term=30646039
  22. Streja E, Gosmanova EO, Molnar MZ et al. Association of Continuation of Statin Therapy Initiated Before Transition to Chronic Dialysis Therapy With Mortality After Dialysis Initiation. JAMA network open 2018; 1:e182311. http://www.ncbi.nlm.nih.gov/pubmed/?term=30646217
  23. Omori M, Okuma Y, Hakozaki T, Hosomi Y. Statins improve survival in patients previously treated with nivolumab for advanced non-small cell lung cancer: An observational study. Molecular and clinical oncology 2019; 10:137-143. http://www.ncbi.nlm.nih.gov/pubmed/?term=30655989
  24. Ezetimibe + statin: insufficient benefit. Prescrire international 2016; 25:245-246. http://www.ncbi.nlm.nih.gov/pubmed/?term=30645833
  25. Rizwan M, Aridi HD, Dang T et al. Long-Term Outcomes of Carotid Endarterectomy and Carotid Artery Stenting When Performed by a Single Vascular Surgeon. Vascular and endovascular surgery 2019:1538574418823379. http://www.ncbi.nlm.nih.gov/pubmed/?term=30614413

Women and elderly

  1. Bezin J, Moore N, Mansiaux Y et al. Real-life benefits of statins for cardiovascular prevention in elderly subjects: a population-based cohort study. Am J Med 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30660573
  2. Molina-Sotomayor E, Arreguin-Moreno R, Rodriguez-Rodriguez F et al. [Effects of exercise on the cognition of older women treated with lovastatin]. Biomedica : revista del Instituto Nacional de Salud 2018; 38:496-506. http://www.ncbi.nlm.nih.gov/pubmed/?term=30653863
  3. Campitelli MA, Maxwell CJ, Maclagan LC et al. One-year survival and admission to hospital for cardiovascular events among older residents of long-term care facilities who were prescribed intensive- and moderate-dose statins. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2019; 191:E32-e39. http://www.ncbi.nlm.nih.gov/pubmed/?term=30642823
  4. Gill SS. All, some or none? Statin prescribing for frail older adults. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2019; 191:E30-e31. http://www.ncbi.nlm.nih.gov/pubmed/?term=30642822
  5. Yandrapalli S, Gupta S, Andries G et al. Drug Therapy of Dyslipidemia in the Elderly. Drugs Aging 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30613912
  6. Matsuo K, Hom MS, Yabuno A et al. Association of statins, aspirin, and venous thromboembolism in women with endometrial cancer. Gynecologic oncology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30616901
  7. Nabati M, Janbabai G, Esmailian J, Yazdani J. Effect of Rosuvastatin in Preventing Chemotherapy-Induced Cardiotoxicity in Women With Breast Cancer: A Randomized, Single-Blind, Placebo-Controlled Trial. Journal of cardiovascular pharmacology and therapeutics 2019:1074248418821721. http://www.ncbi.nlm.nih.gov/pubmed/?term=30599756
  8. van der Ploeg MA, Streit S, Achterberg WP et al. Patient Characteristics and General Practitioners' Advice to Stop Statins in Oldest-Old Patients: a Survey Study Across 30 Countries. Journal of general internal medicine 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30652277
  9. Pitha J, Topinkova E, Blaha V et al. Statin therapy in elderly patients. Vnitr Lek 2018; 64:1021-1027. http://www.ncbi.nlm.nih.gov/pubmed/?term=30606018
 
 
 
 
 
Twitter
IAS Website
For information
You are now on the editors mailing list of the IAS Statin Newsletter.
The IAS Statin Newsletter is part of the IAS News and Literature update service.
 
This activity is supported by an educational grant from Pfizer.